Cargando…

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome

Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterised by an increased risk for non-Hodgkin lymphoma (NHL) development. Ectopic germinal centre (GC) in the salivary gland is associated with increased NHL risk in pSS, and the chemokine CXCL13 is implicated in B-cell migration and GC...

Descripción completa

Detalles Bibliográficos
Autores principales: Traianos, Emmanuella Young, Locke, James, Lendrem, Dennis, Bowman, Simon, Hargreaves, Ben, Macrae, Victoria, Tarn, Jessica Rachael, Ng, Wan-Fai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069897/
https://www.ncbi.nlm.nih.gov/pubmed/32047959
http://dx.doi.org/10.1007/s00296-020-04524-5
_version_ 1783505861358911488
author Traianos, Emmanuella Young
Locke, James
Lendrem, Dennis
Bowman, Simon
Hargreaves, Ben
Macrae, Victoria
Tarn, Jessica Rachael
Ng, Wan-Fai
author_facet Traianos, Emmanuella Young
Locke, James
Lendrem, Dennis
Bowman, Simon
Hargreaves, Ben
Macrae, Victoria
Tarn, Jessica Rachael
Ng, Wan-Fai
author_sort Traianos, Emmanuella Young
collection PubMed
description Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterised by an increased risk for non-Hodgkin lymphoma (NHL) development. Ectopic germinal centre (GC) in the salivary gland is associated with increased NHL risk in pSS, and the chemokine CXCL13 is implicated in B-cell migration and GC formation. Serum CXCL13 concentrations were quantified by ELISA in 48 healthy individuals, 273 pSS patients without NHL (pSS-nonL), and 38 pSS patients with NHL (pSS-NHL+) from the United Kingdom Primary Sjögren’s Syndrome Registry cohort. PSS-nonL patients were stratified into low risk (LR), moderate risk (MR) and high risk (HR) groups according to the lymphoma risk score proposed by Fragkioudaki et al. Differences in serum CXCL13 levels among groups were analysed using the Wilcoxon method. Also, changes in serum CXCL13 over a time period of at least 1 year and a median 4 years were assessed for 200 pSS-nonL and 8 pSS-NHL+ patients. In addition, associations of serum CXCL13 with B-cell and inflammatory markers were investigated by correlation analyses and logistic regression. Serum CXCL13 levels were higher in all pSS groups compared to controls (p < 0.0001), and in pSS-NHL+ compared to pSS-nonL patients (p = 0.0204). LR patients had lower CXCL13 levels than MR patients (p < 0.0001) and pSS-NHL+ patients (p = 0.0008). CXCL13 levels remained stable over the study period for all pSS groups. CXCL13 was associated (p < 0.0005) with Immunoglobulin G (IgG), B-cell activating factor, β2 microglobulin, combined free light chains, κ and λ light chains, anti-Ro/SSA, anti-La/SSB, and erythrocyte sedimentation rate. IgG and C3 controlled for age and gender were significantly associated with NHL risk in pSS. Serum CXCL13 levels were elevated in pSS-NHL+ and MR patients compared to LR patients and remained stable over time. Further study is required to investigate the role of CXCL13 in pSS-associated NHL risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00296-020-04524-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7069897
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-70698972020-03-23 Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome Traianos, Emmanuella Young Locke, James Lendrem, Dennis Bowman, Simon Hargreaves, Ben Macrae, Victoria Tarn, Jessica Rachael Ng, Wan-Fai Rheumatol Int Comorbidities Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterised by an increased risk for non-Hodgkin lymphoma (NHL) development. Ectopic germinal centre (GC) in the salivary gland is associated with increased NHL risk in pSS, and the chemokine CXCL13 is implicated in B-cell migration and GC formation. Serum CXCL13 concentrations were quantified by ELISA in 48 healthy individuals, 273 pSS patients without NHL (pSS-nonL), and 38 pSS patients with NHL (pSS-NHL+) from the United Kingdom Primary Sjögren’s Syndrome Registry cohort. PSS-nonL patients were stratified into low risk (LR), moderate risk (MR) and high risk (HR) groups according to the lymphoma risk score proposed by Fragkioudaki et al. Differences in serum CXCL13 levels among groups were analysed using the Wilcoxon method. Also, changes in serum CXCL13 over a time period of at least 1 year and a median 4 years were assessed for 200 pSS-nonL and 8 pSS-NHL+ patients. In addition, associations of serum CXCL13 with B-cell and inflammatory markers were investigated by correlation analyses and logistic regression. Serum CXCL13 levels were higher in all pSS groups compared to controls (p < 0.0001), and in pSS-NHL+ compared to pSS-nonL patients (p = 0.0204). LR patients had lower CXCL13 levels than MR patients (p < 0.0001) and pSS-NHL+ patients (p = 0.0008). CXCL13 levels remained stable over the study period for all pSS groups. CXCL13 was associated (p < 0.0005) with Immunoglobulin G (IgG), B-cell activating factor, β2 microglobulin, combined free light chains, κ and λ light chains, anti-Ro/SSA, anti-La/SSB, and erythrocyte sedimentation rate. IgG and C3 controlled for age and gender were significantly associated with NHL risk in pSS. Serum CXCL13 levels were elevated in pSS-NHL+ and MR patients compared to LR patients and remained stable over time. Further study is required to investigate the role of CXCL13 in pSS-associated NHL risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00296-020-04524-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-02-11 2020 /pmc/articles/PMC7069897/ /pubmed/32047959 http://dx.doi.org/10.1007/s00296-020-04524-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Comorbidities
Traianos, Emmanuella Young
Locke, James
Lendrem, Dennis
Bowman, Simon
Hargreaves, Ben
Macrae, Victoria
Tarn, Jessica Rachael
Ng, Wan-Fai
Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
title Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
title_full Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
title_fullStr Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
title_full_unstemmed Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
title_short Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
title_sort serum cxcl13 levels are associated with lymphoma risk and lymphoma occurrence in primary sjögren’s syndrome
topic Comorbidities
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069897/
https://www.ncbi.nlm.nih.gov/pubmed/32047959
http://dx.doi.org/10.1007/s00296-020-04524-5
work_keys_str_mv AT traianosemmanuellayoung serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT lockejames serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT lendremdennis serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT bowmansimon serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT hargreavesben serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT macraevictoria serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT tarnjessicarachael serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome
AT ngwanfai serumcxcl13levelsareassociatedwithlymphomariskandlymphomaoccurrenceinprimarysjogrenssyndrome